#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Germany Spain

  • Study of personalized tamoxifen dosing (10mg, 20mg, or 40mg daily) compared to standard dose (20mg) in women with breast cancer to improve treatment continuation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Sweden

  • Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Germany Portugal

  • Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Portugal

  • Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Spain

  • Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study of abemaciclib and its connection to severe diarrhea in patients with hormone receptor-positive breast cancer at high risk of return

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    France